
Absci rose 165.0% from $2.86 to $7.58, ahead of the S&P 500's +10.0%. Its worst day was Jul 16 (−15.7%), and its low came Mar 12 at $2.30.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Absci closed at its lowest level of the year, 19.6% below where the year started.
−6.1% · S&P 500 −1.5%
EPS of $-0.20 missed the $-0.17 estimate on $650,000.00 revenue (est. $2.3M).
Story events cover the past 12 months · Times ET
−3.0% · S&P 500 +0.6%
Absci shares rose 23.1%, while the S&P 500 rose 0.2%.
+23.1% · S&P 500 +0.2%
EPS of $-0.19 beat the $-0.20 estimate on $215,000.00 revenue (est. $1.6M).
+2.6% · S&P 500 +0.8%
Absci shares rose 23.6%, while the S&P 500 rose 0.4%.
+23.6% · S&P 500 +0.4%
Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month periodFirst multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic
+36.0%, the year's best day, on 38M shares, the year's heaviest volume · S&P 500 0.0%
EPS of $-0.21 missed the $-0.19 estimate on $318,000.00 revenue (est. $1.3M).
+1.0% · S&P 500 +0.3%
Absci closed at its highest level of the year, 323.1% above where the year started.
+1.9% · S&P 500 −0.4%
EPS of $-0.19 beat the $-0.19 estimate on $304,000.00 revenue (est. $991,360.00).
−9.7% · S&P 500 −0.4%
Where it ended: a close of $7.58 on Nov 17, 2026.
Nothing in the past 12 months.
All ABSI dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ABSI and SPY from Benzinga historical bars. Not investment advice.